Condition: Congenital Heart Surgery · Congenital Heart Disease in Children · Fontan Physiology · Sponsor: Martin Schweiger
Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.
This description comes directly from the study's public registry record.
Martin Schweiger, Prof, MD, MBA · +41 44 249 6511 · sst2@kispi.uzh.ch
Clemens Haselmann, MD
Always discuss trial participation with your own doctor first.
| University Children's Hospital Zurirch | Zurich, Canton of Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07029230